ExodusPoint Capital Management LP Takes $436,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

ExodusPoint Capital Management LP acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,244 shares of the biopharmaceutical company's stock, valued at approximately $436,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CLDX. Cinctive Capital Management LP grew its position in shares of Celldex Therapeutics by 140.6% in the fourth quarter. Cinctive Capital Management LP now owns 81,320 shares of the biopharmaceutical company's stock valued at $2,055,000 after purchasing an additional 47,523 shares during the period. Bryce Point Capital LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter worth about $601,000. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter worth approximately $81,000. JPMorgan Chase & Co. grew its holdings in Celldex Therapeutics by 103.3% in the fourth quarter. JPMorgan Chase & Co. now owns 85,545 shares of the biopharmaceutical company's stock valued at $2,162,000 after purchasing an additional 43,470 shares during the period. Finally, Vanguard Group Inc. raised its stake in Celldex Therapeutics by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock worth $98,098,000 after purchasing an additional 12,213 shares during the period.

Celldex Therapeutics Stock Performance

NASDAQ CLDX traded up $0.50 on Friday, reaching $18.30. The company's stock had a trading volume of 457,867 shares, compared to its average volume of 881,015. The firm's 50 day moving average is $19.61 and its two-hundred day moving average is $24.01. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00. The stock has a market cap of $1.21 billion, a PE ratio of -7.12 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CLDX has been the topic of several research reports. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group decreased their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. UBS Group began coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, Morgan Stanley initiated coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.